Shaun Mahaffy’s practice focuses on patent litigation, primarily in the pharmaceutical and biotechnology fields. Shaun has represented clients in Hatch-Waxman and jury trials, in appellate proceedings in the Court of Appeals for the Federal Circuit, and in inter partes proceedings before the PTO.
Shaun graduated summa cum laude from Vanderbilt University in 2005 and received his Ph.D. in Neuroscience from the University of California San Diego in 2010. In 2013 he received his J.D. from Yale Law School, where he was the Executive Editor for the Yale Law Journal. Before joining Williams & Connolly in 2015, Shaun clerked for the Honorable Ellen S. Huvelle on the United States District Court for the District of Columbia and for the Honorable Paul V. Niemeyer on the United States Court of Appeals for the Fourth Circuit.
Though all cases vary and none is predictive, Shaun’s experience includes:
- Represented Teva’s Branded Division in a Hatch-Waxman trial in the District of Delaware, relating to multiple generic manufacturers’ applications to market a generic version of its Bendeka® product. After a seven day bench trial, the court upheld the validity of all claims in all five patents.
- Represented Merck in Hatch-Waxman patent litigation involving Januvia® (sitagliptin) in both the district court and in co-pending IPR proceedings. After trials in the PTAB and then the district court, the PTAB upheld all claims of the patent-at-issue, and the district court found all challenged claims infringed and not invalid.
- Represented bioMérieux in patent litigation involving diagnostic kits for the detection of HIV virus in blood products in the both the PTAB and federal district court.
- Represented Alcon in Hatch-Waxman litigation related to its Ilevro® product.
- Represented Regeneron in its BPCIA litigation regarding Eylea, pending in the Northern District of West Virginia.